Page last updated: 2024-10-27

vanoxerine and Tuberculosis, Multidrug-Resistant

vanoxerine has been researched along with Tuberculosis, Multidrug-Resistant in 1 studies

vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.

Tuberculosis, Multidrug-Resistant: Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kanvatirth, P1
Jeeves, RE1
Bacon, J1
Besra, GS1
Alderwick, LJ1

Other Studies

1 other study available for vanoxerine and Tuberculosis, Multidrug-Resistant

ArticleYear
Utilisation of the Prestwick Chemical Library to identify drugs that inhibit the growth of mycobacteria.
    PloS one, 2019, Volume: 14, Issue:3

    Topics: Agar; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Drug Design; Drug Reposit

2019